- Home
- SKWD vs GENB Comparison
SKWD vs GENB Comparison
Compare SKWD & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SKWD | GENB |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKWD | GENB |
|---|---|---|
| Price | $44.10 | $14.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $64.63 | $23.20 |
| AVG Volume (30 Days) | ★ 327.6K | 294.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | N/A |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $1,416,541,000.00 | N/A |
| Revenue This Year | $29.54 | N/A |
| Revenue Next Year | $12.64 | $16.58 |
| P/E Ratio | $11.15 | ★ N/A |
| Revenue Growth | ★ 23.16 | N/A |
| 52 Week Low | $40.60 | $11.00 |
| 52 Week High | $65.05 | $14.21 |
Technical Indicators
Market Signals| Indicator | SKWD | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 65.28 |
| Support Level | $43.55 | $11.52 |
| Resistance Level | $50.29 | N/A |
| Average True Range (ATR) | 1.31 | 0.77 |
| MACD | -0.20 | 0.13 |
| Stochastic Oscillator | 0.26 | 81.65 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.